EEF2K and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: Even though future studies focused on clarifying the activity of eEF2K inhibition on Dravet syndrome comorbidity are necessary, our data suggest eEF2K pharmacological inhibition as an innovative therapy for Dravet syndrome.